Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a biologic drug tame a rare vasculitis and cut steroid use?

NCT ID NCT07815886

Disease control Sponsor: European EGPA Study Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are studying how well benralizumab works in adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that inflames blood vessels and can affect the lungs, nerves, and sinuses. The study follows about 100 patients at European referral centers who receive benralizumab every 4 weeks, either as their first biologic or after another drug. Over up to 24 months, researchers will track disease activity, lung function, steroid doses, relapses, and side effects from medical records. The goal is to understand whether benralizumab helps patients control EGPA and reduce their need for oral steroids in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
benralizumab, a biologic drug given every 4 weeks
What this could lead to
If benralizumab helps, it could offer people with EGPA a way to control symptoms and lower their daily steroid dose over the long term.
What could go wrong
This is an observational study of about 100 people, so it cannot prove cause and effect. Results may not apply to everyone with EGPA, and benralizumab carries known risks such as allergic reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Patients may be newly diagnosed or have relapsing or refractory EGPA, and will be included if at least 3 months of follow-up data after benralizumab initiation are available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria or the criteria proposed in the MIRRA trial. * Treatment with benralizumab 30 mg every 4 weeks. * At least 3 months of available follow-up data after starting benralizumab. * Written informed consent for study participation and data collection. Exclusion Criteria: * Age younger than 18 years. * No available follow-up data after starting benralizumab. * Follow-up after benralizumab initiation shorter than 3 months. * Lack of written informed consent, where required by local regulations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eosinophilic granulomatosis with polyangiitis (EGPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eosinophilic granulomatosis with polyangiitis (EGPA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Edoardo Biancalana

    RECRUITING

    Florence, Italy, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.